251 related articles for article (PubMed ID: 12187957)
1. Immunohistochemical markers for prognosis of cerebral glioblastomas.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):217-36. PubMed ID: 12187957
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases.
Korshunov A; Golanov A; Sycheva R; Pronin I
J Clin Pathol; 1999 Aug; 52(8):574-80. PubMed ID: 10645226
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.
Bouvier-Labit C; Chinot O; Ochi C; Gambarelli D; Dufour H; Figarella-Branger D
Neuropathol Appl Neurobiol; 1998 Oct; 24(5):381-8. PubMed ID: 9821169
[TBL] [Abstract][Full Text] [Related]
4. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical markers for prognosis of ependymal neoplasms.
Korshunov A; Golanov A; Timirgaz V
J Neurooncol; 2002 Jul; 58(3):255-70. PubMed ID: 12187959
[TBL] [Abstract][Full Text] [Related]
6. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients.
Simmons ML; Lamborn KR; Takahashi M; Chen P; Israel MA; Berger MS; Godfrey T; Nigro J; Prados M; Chang S; Barker FG; Aldape K
Cancer Res; 2001 Feb; 61(3):1122-8. PubMed ID: 11221842
[TBL] [Abstract][Full Text] [Related]
7. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
[TBL] [Abstract][Full Text] [Related]
8. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
9. p53 mutations versus EGF receptor expression in giant cell glioblastomas.
Peraud A; Watanabe K; Plate KH; Yonekawa Y; Kleihues P; Ohgaki H
J Neuropathol Exp Neurol; 1997 Nov; 56(11):1236-41. PubMed ID: 9370234
[TBL] [Abstract][Full Text] [Related]
10. Molecular Subgroups of Glioblastoma- an Assessment by Immunohistochemical Markers.
Nagy Á; Garzuly F; Padányi G; Szűcs I; Feldmann Á; Murnyák B; Hortobágyi T; Kálmán B
Pathol Oncol Res; 2019 Jan; 25(1):21-31. PubMed ID: 28948518
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
12. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
13. [The prognostic importance of cancer-associated proteins and apoptosis in glioblastomas of the cerebral hemispheres].
Korshunov AG; Golanov AV; Sycheva RV; Pronin IN
Zh Vopr Neirokhir Im N N Burdenko; 1999; (1):3-7. PubMed ID: 10335568
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of the apoptotic index analysed jointly with selected cell cycle regulators and proliferation markers in non-small cell lung cancer.
Dworakowska D; Jassem E; Jassem J; Karmoliński A; Lapiński M; Tomaszewski D; Rzyman W; Jaśkiewicz K; Sworczak K; Grossman AB
Lung Cancer; 2009 Oct; 66(1):127-33. PubMed ID: 19200616
[TBL] [Abstract][Full Text] [Related]
15. Clinical and immunohistochemical prognostic factors in adult glioblastoma patients.
Umesh S; Tandon A; Santosh V; Anandh B; Sampath S; Chandramouli BA; Sastry Kolluri VR
Clin Neuropathol; 2009; 28(5):362-72. PubMed ID: 19788052
[TBL] [Abstract][Full Text] [Related]
16. A simplified approach for the molecular classification of glioblastomas.
Le Mercier M; Hastir D; Moles Lopez X; De Nève N; Maris C; Trepant AL; Rorive S; Decaestecker C; Salmon I
PLoS One; 2012; 7(9):e45475. PubMed ID: 23029035
[TBL] [Abstract][Full Text] [Related]
17. Combined epidermal growth factor receptor and Beclin1 autophagic protein expression analysis identifies different clinical presentations, responses to chemo- and radiotherapy, and prognosis in glioblastoma.
Tini P; Belmonte G; Toscano M; Miracco C; Palumbo S; Pastina P; Battaglia G; Nardone V; Butorano MA; Masucci A; Cerase A; Pirtoli L
Biomed Res Int; 2015; 2015():208076. PubMed ID: 25821789
[TBL] [Abstract][Full Text] [Related]
18. The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients.
Yoshida Y; Nakada M; Harada T; Tanaka S; Furuta T; Hayashi Y; Kita D; Uchiyama N; Hayashi Y; Hamada J
J Neurooncol; 2010 May; 98(1):41-7. PubMed ID: 19937366
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
[No Abstract] [Full Text] [Related]
20. Immunohistochemical expression of stem cell markers CD44 and nestin in glioblastomas: Evaluation of their prognostic significance.
Guadagno E; Borrelli G; Califano M; Calì G; Solari D; Del Basso De Caro M
Pathol Res Pract; 2016 Sep; 212(9):825-32. PubMed ID: 27450656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
